The role of rosuvastatin in the treatment of pediatric homozygous familial hypercholesterolemia

Expert Opinion on Orphan Drugs

Volumn 2, Issue 12, 2014, Pages 1325-1330

  Braamskamp, Marjet J A M ^a   Roelants, Roosje J ^a   Hutten, Barbara A ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Children; Homozygous familial hypercholesterolemia; Rosuvastatin; Statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; ARTERIAL WALL THICKNESS; ARTICLE; CHILD; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HEMATURIA; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; PROTEINURIA; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 84912072557     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.958467     Document Type: Article

References (33)

1. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotypephenotype relationship, and clinical outcome. Eur Heart J 2014. [Epub ahead of print
2. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013;34(45):3478-90a
3. Goldstein JL, Hobbs HH, Brown MS. PART 12: LIPIDS Chapter 120: familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editor. The metabolic and molecular bases of inherited disease. 8th edition. 2001. p. 2863-913
4. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on Diagnosis and treatment. Atherosclerosis 2012;223(2):262-8
5. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35(32):2146-5
6. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008;102(11):1438-43
7. Macchiaiolo M, Gagliardi MG, Toscano A, et al. Homozygous familial hypercholesterolaemia. Lancet 2012;379(9823):1330
8. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004;15(4):413-22
9. Marais AD, Raal FJ, Stein EA, et al. A dose-Titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008;197(1):400-6
10. Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- And Nmethanesulfonyl a novel series of HMGCoA reductase inhibitors. 1997;5(2):437-44
11. McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 2005;62(10):1033-47
12. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25(10):2553-63
13. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25(11):2822-35
14. Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003;25(8):2215-24
15. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42(10):1116-21
16. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003;4(1):9-14
17. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78
18. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92(2):152-60
19. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in lowrisk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297(12):1344-53
20. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295(13):1556-65
21. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207
22. Raal FJ, Pappu AS, Illingworth DR, et al Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. 2000;150:421-8
23. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198(2):247-55
24. Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55(11):1121-6
25. Stein EA, Strutt K, Southworth H, et al. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003;92(11):1287-93
26. Kusters DM, Hutten BA, McCrindle BW, et al. Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. J Clin Lipidol 2013;7(5):408-13
27. Langslet G, Braamskamp MJAM, McCrindle B, et al. Effect of rosuvastatin therapy on arterial wall changes in children and adolescents with familial hypercholesterolemia: results from the CHARON study. J Am Coll Cardiol 2014;63(12):A1379
28. Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-Treated patients in a multinational clinical trial program. Cardiology 2007;107(4):433-43
29. Stein EA, Marais AD, Ducobu J, et al. Comparison of short-Term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-Term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia. J Clin Lipidol 2007;1(4):287-99
30. Stein EA, Vidt DG, Shepherd J, et al. Renal safety of intensive cholesterollowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis 2012;221(2):471-7
31. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-Analysis of randomised statin trials. Lancet 2010;375(9716):735-42
32. Navarese EP, Buffon A, Andreotti F, et al. Meta-Analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111(8):1123-30
33. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380(9841):565-71